Does DSIP actually improve sleep?

While originally identified for sleep-inducing properties, clinical results have been variable. Some studies show benefits for sleep quality, while others have not replicated these findings. It is not an approved sleep medication.

What is DSIP used for?

DSIP has been researched for sleep disorders, chronic pain, stress management, and substance dependence. It has been used clinically in some European countries, though it is not widely approved.

DSIP has generally shown a good safety profile in studies, but comprehensive long-term safety data is limited. Any use should be approached cautiously and ideally under medical supervision.

Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 1 February 2026

Share:X Post LinkedIn

Cognitive & Neurological•Updated 2026-02-01•5 min read

What Is DSIP? Benefits, Research & Safety

A neuropeptide originally isolated for its sleep-inducing properties, now researched for stress protection, pain modulation, and metabolic effects.

Share:X Post LinkedIn

Also known as:

Delta Sleep-Inducing Peptide

DSIP Peptide

DAnimal/cell evidence onlyUK: Sold as 'research only' (UK)WADA: Sport status unclear

UK summary: Not a licensed UK medicine. Endogenous peptide investigated for sleep, pain, and stress-protection in older Russian / Eastern European studies; modern human evidence is sparse.

Quick Facts

Overview

Delta Sleep-Inducing Peptide (DSIP) is a naturally occurring nonapeptide (nine amino acids) first isolated from rabbit brain in 1977. It was initially identified for its ability to induce delta wave (deep) sleep in rabbits, leading to its name. DSIP is found in the brain, pituitary gland, and peripheral tissues of mammals, including humans. Despite its name, subsequent research has revealed that DSIP's effects are broader than sleep induction alone, encompassing stress protection, pain modulation, hormone regulation, and potential effects on substance dependence. The peptide has been studied for various applications including treatment of insomnia and sleep disorders, management of chronic pain, protection against stress, and as an adjunct in treating opioid and alcohol dependence. Some studies have also explored its effects on hormonal balance and metabolic parameters. DSIP has been used clinically in some European countries, particularly for sleep disorders and chronic pain. However, it is not widely approved, and research results have been somewhat inconsistent across different studies and populations. DSIP is not approved in the UK or most of the EU and remains a research compound in these regions.

Evidence standards summary

DSIP — evidence and risk at a glance

Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.

01Evidence snapshot

DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.

Not a licensed UK medicine. Endogenous peptide investigated for sleep, pain, and stress-protection in older Russian / Eastern European studies; modern human evidence is sparse.

02Human evidence grade

ETheoretical / insufficientStrength of evidence from published human trials.

03Preclinical evidence grade

DAnimal/cell evidence onlyAnimal-model and in-vitro evidence quality.

04Regulatory status

UK: Not licensed for human use. Research compound only.
EU: Not widely approved; limited clinical use in some countries historically.
Notes: DSIP has been used clinically in some European countries but is not widely approved. Regulatory status varies. Not available through standard medical channels in the UK.

05Approved medical uses

None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)

06Unapproved / promotional claims

Restores natural delta-wave sleep without side effects.
Effective treatment for chronic insomnia.
Non-addictive alternative to Z-drugs and benzodiazepines.
Improves stress resilience and HPA-axis function.

07Common internet claims

Marketed as the original sleep peptide for biohackers.
Sold by online retailers as a research-only injection or nasal spray.
Recommended in longevity stacks for sleep-architecture optimisation.

08Claim vs evidence

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Cures insomnia naturally”	D	Limited	High	Older studies suggest sleep effects; modern controlled human evidence is limited. Insomnia should be assessed by a clinician.
“Safe non-addictive sleep aid”	E	No	High	Long-term human safety is not established.

09Safety uncertainty score

High

Limited human safety data; meaningful uncertainty about rare or long-term effects.

10Known adverse signals

Limited systematic safety data.
Injection-site reactions.
Unknown chronic effects on neuroendocrine signalling.
Interactions with sedatives, alcohol, and SSRIs unstudied.

11Drug-interaction uncertainty

High

Interaction picture sparse; meaningful uncertainty when combined with other medicines.

12Anti-doping status

WADA: Sport status unclearWADA strict-liability framing applies.

13UK legal position

UK: Sold as 'research only' (UK)

Not licensed for human use. Research compound only.

Read the full UK legal guide → Research peptides and UK law

14EU legal position

Not widely approved; limited clinical use in some countries historically.

15What this page cannot tell you

Whether a UK-purchased vial contains DSIP at the labelled concentration.
How chronic use affects natural sleep-cycle regulation.
Whether it adds risk in combination with prescribed sleep medications.
What the effective dose is in humans — no licensed reference exists.

16Last reviewed

Last reviewed: 1 February 2026

Next review due: 1 February 2027

Spotted an error or something out of date? Send a correction.

17Citation quality score

DAnimal/cell evidence onlyQuality of the sources we cite, graded against the evidence grading methodology.

18Research gaps

Most positive data comes from 1970s-1980s Eastern European studies with limited modern replication.
No registered Western Phase 3 trials.
Mechanism of action is not fully characterised even after 50 years.
Long-term safety unstudied.

19Safer alternatives / established care pathways

CBT for insomnia (CBT-I) via NHS Talking Therapies — NICE first-line.
Sleep hygiene fundamentals (caffeine, alcohol, light, schedule).
Licensed melatonin (Circadin) for over-55s with primary insomnia.
GP review for sleep apnoea, depression, or other underlying causes.

20Doctor discussion prompts

Questions to ask a qualified clinician

These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.

Is DSIP a licensed UK medicine?
What licensed UK sleep treatments should be considered first?
Should my insomnia be investigated for an underlying cause?

Discovery & History

DSIP was discovered in 1977 by a Swiss research group led by Monnier and Schoenenberger. They were investigating sleep-promoting factors in the blood of sleeping rabbits and isolated a peptide that could induce delta wave (deep, slow-wave) sleep when injected into the brains of awake rabbits. The peptide was subsequently characterised as a nonapeptide with the sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu. It was found to be present in various mammals, including humans. Throughout the 1980s and 1990s, research expanded to explore DSIP's effects beyond sleep. Studies revealed potential applications in stress protection, pain management, and treatment of various conditions. DSIP was used clinically in some European countries, particularly Switzerland and Germany. Research results, however, have been variable. While some studies showed promising effects, others failed to replicate findings. This inconsistency has complicated the clinical development pathway. Interest in DSIP has continued, particularly in research settings exploring its mechanisms of action and potential applications. It remains an intriguing neuropeptide with effects that extend beyond its original sleep-inducing characterisation.

Mechanism of Action

DSIP's mechanisms of action are not fully elucidated, but several effects have been identified: **Sleep Regulation** DSIP appears to promote delta wave sleep through interactions with sleep-regulating systems, though the exact mechanisms are debated. It may influence GABAergic, serotonergic, and other neurotransmitter systems involved in sleep. **Stress Response Modulation** DSIP has been shown to modulate the hypothalamic-pituitary-adrenal (HPA) axis response to stress, potentially providing protective effects against chronic stress. **Endogenous Opioid Interaction** Research suggests DSIP may interact with endogenous opioid systems, which could explain some of its pain-modulating and dependence-treatment effects. **Hormone Regulation** DSIP appears to influence various hormone systems, including growth hormone, cortisol, and thyroid hormones, though effects vary across studies. **Antioxidant Effects** Some research indicates DSIP may have antioxidant properties, potentially providing neuroprotective effects. **Pain Modulation** DSIP has demonstrated analgesic properties in some studies, possibly through interaction with opioid systems or other pain-modulating pathways.

Researched Benefits

Based on preclinical and clinical research findings:

1
Potential improvement in sleep quality and delta wave sleep
2
Stress-protective effects in some research
3
Pain modulation and analgesic properties
4
Possible benefits in substance dependence treatment
5
Hormonal regulation effects
6
Antioxidant and neuroprotective properties

Claim vs Evidence

How popular claims about DSIP stack up against the current research, graded using our public evidence grading methodology.

Claim	Evidence	Human evidence?	Regulatory concern	Safer wording
“Cures insomnia naturally”	D	Limited	High	Older studies suggest sleep effects; modern controlled human evidence is limited. Insomnia should be assessed by a clinician.
“Safe non-addictive sleep aid”	E	No	High	Long-term human safety is not established.

Theoretical Dosing & Protocols

⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.

Theoretical Dosage	100-300 mcg per administration (based on various research protocols)
Frequency	Once daily, typically in the evening
Duration	Variable; typically several weeks in clinical studies
Notes	Protocols vary significantly across studies. DSIP is not approved in the UK/EU. Any use should be approached with caution and ideally under medical supervision.

Administration Routes

Routes studied in research settings (educational only):

Subcutaneous injection
Intravenous injection (clinical settings)
Intranasal (some formulations)

Half-Life	Stability
Relatively short; approximately 15-25 minutes in circulation	Lyophilised powder should be stored refrigerated or frozen

Safety Profile & Known Risks

Commonly Reported Side Effects

Generally well-tolerated in studies
Headache in some individuals
Transient nausea
Injection site reactions

Rare Risks & Concerns

Limited comprehensive safety data
Potential effects on hormone systems with chronic use
Long-term effects unknown

Contraindications

Pregnancy and breastfeeding
Severe depression or psychiatric disorders
Hormone-sensitive conditions
Children and adolescents

UK & EU Regulatory Context

🇬🇧 United Kingdom

Not licensed for human use. Research compound only.

🇪🇺 European Union

Not widely approved; limited clinical use in some countries historically.

DSIP has been used clinically in some European countries but is not widely approved. Regulatory status varies. Not available through standard medical channels in the UK.

Clinical Studies Summary

Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.

Data analysis suggested, however, that the statistically significant effects were weak and in part could be due to an incidental change in the placebo group. As none of the other measures, including subjective sleep quality, showed any change, it was concluded that short-term treatment of chronic insomnia with DSIP is not likely to be of major therapeutic benefit.

Neuropsychobiology. 1992View on PubMed

Delta-sleep-inducing peptide does not affect CRH and meal-induced ACTH and cortisol secretion.

Meal-related midday surge of ACTH and cortisol was also not affected by DSIP. Our data do not support an inhibitory role of DSIP on ACTH and cortisol secretion in man.

Psychoneuroendocrinology. 1995View on PubMed

Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs.

For NREM sleep time and stage 2 sleep differences between DSIP and a placebo were significant, but the same differences existed already for the baseline values. It can be concluded that sleep improvement under DSIP treatment is of little clinical significance.

Int J Clin Pharmacol Res. 1987View on PubMed

Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia.

Alertness and performance at daytime increased significantly. The study demonstrates the efficacy of DSIP for the treatment of impaired sleep and daytime functions as well.

Eur Neurol. 1987View on PubMed

DSIP in insomnia.

A case of insomnia in organic brain disease responded well to higher doses. The results are discussed as to the mode of action of DSIP and its possible therapeutic use in insomnia.

Eur Neurol. 1984View on PubMed

A clinical trial with DSIP.

The mood and performance during the daytime improved as well. A problem may be a long-standing habit of drug addiction.